Owkin signs AI drug discovery deal with Boehringer Ingelheim for cancer and immunology
On September 2, Owkin signed an agreement with Boehringer Ingelheim on AI-based drug discovery in cancer and immunology. The deal is another example of cooperation between large pharmaceutical companies and AI firms.
Who is affected and how
- pharmaceuticals
- The collaboration model shows that large companies are expanding their research pipelines with external AI platforms.
Sources
- Owkin signs AI drug discovery deal with Boehringer for cancer, immunologyreuters · Sep 2, 2026
- Boehringer Ingelheim Licenses Owkin’s K Pro AI Scientist for Accelerated Discovery in Oncology, Immunology | Contract Pharmacontractpharma.com · Sep 2, 2026
- Owkin signs AI drug discovery deal with Boehringer for cancer, immunology - CNBC TV18cnbctv18.com · Sep 2, 2026
- Owkin signs AI drug discovery deal with Boehringer for cancer, immunology | WTVB | 1590 AM · 95.5 FM | The Voice of Branch Countywtvbam.com · Sep 2, 2026
- Boehringer signs AI drug discovery deal with Owkinpharmaphorum · Sep 3, 2026
- Boehringer signs AI drug discovery deal with Owkin | pharmaphorumpharmaphorum.com · Sep 3, 2026
- AI Drug Discovery & Emerging Pharma Technologies in Asiapharmafocusasia.com · Sep 3, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.